- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02388516
Maternal Vitamin D for Acute Respiratory Infections in Infancy (MDARI)
April 18, 2017 updated by: Daniel Roth, The Hospital for Sick Children
Maternal Vitamin D for Acute Respiratory Infections in Infancy (MDARI): a Nested Sub-study in a Randomized Controlled Trial of Vitamin D Supplementation During Pregnancy and Lactation in Dhaka, Bangladesh
There is a growing body of data suggesting that vitamin D modulates the host's immune response to acute respiratory infection (ARI).
The primary aim of this study is to determine whether maternal vitamin D3 supplementation versus placebo decreases the incidence rate of microbiologically confirmed viral-associated ARI among infants in Dhaka, Bangladesh.
Secondary outcomes include: A) incidence of ARI associated with specific major pathogens, B) incidence of clinical ARI (without the need for positive microbiology), and C) quantitative density of pneumococcal carriage.
Infants will be followed from birth until 6 months of life.
Among infants who meet at least one of the specific case definitions for ARI (see 'Detailed Description' section), nasal swab specimens will be collected.
Respiratory samples will be analyzed by real-time polymerase chain reaction (qPCR) to identify a 7-virus panel (influenza A and B, respiratory syncytial virus, human metapneumovirus, adenovirus, and parainfluenza types 1, 2, and 3) plus quantitative density of S. pneumonia.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
In this study, an acute respiratory infection (URTI and/or LRTI) has been clinically defined as:
A) Upper respiratory tract infection (URTI)
A new-onset illness consisting of at least two of the following clinical criteria at any time during a surveillance week:
- Caregiver-reported cough;
- Caregiver-reported rhinorrhea;
- Caregiver-reported nasal congestion; and,
- Measured axillary temperature greater than or equal to 37.5°C.
B) Lower respiratory tract infection (LRTI)
New onset clinically-diagnosed LRTI:
- Caregiver-reported cough AND/OR difficulty breathing during a surveillance week; AND,
- Observed lower chest wall indrawing AND/OR elevated respiratory rate (60 breaths per minute or greater for infant up to 59 days of age, or 50 breaths per minute or greater for infant 60 days of age or older)
Hospitalized LRTI
- Hospitalization with physician diagnosis of pneumonia or bronchiolitis
Study Type
Interventional
Enrollment (Actual)
1214
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dhaka, Bangladesh
- International Centre for Diarrhoeal Disease Research, Bangldesh
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day to 5 months (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Infants born to women enrolled in the MDIG trial (NCT01924013).
- Maternal inclusion criteria (at time of enrolment) will be:
- At least 18 years of age
- 17 to 24 completed weeks of gestation
- Intends to permanently reside in the trial catchment area for at least 18 months
- Family plans to reside in catchment area for the first 6 months postnatal
- Provides written informed consent for participation
Exclusion Criteria:
- Mother withdrawn from MDIG trial prior to delivery
- Failure to provide consent for participation in sub-study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Group A
Prenatal Period 0 IU; Postpartum Period 0 IU (placebo) Overall: The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery.
The Postpartum Period will last from delivery until 6 months postpartum.
|
|
Experimental: Group B
Prenatal Period 4,200 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
|
Other Names:
|
Experimental: Group C
Prenatal Period 16,800 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
|
Other Names:
|
Experimental: Group D
Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
|
Other Names:
|
Experimental: Group E
Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 28,000 IU/week
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Microbiologically confirmed viral acute respiratory infection (URTI and/or LRTI)
Time Frame: 0 to 6 months
|
0 to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ARI with microbiologically confirmed influenza A or B
Time Frame: 0 to 6 months
|
0 to 6 months
|
ARI with microbiologically confirmed RSV
Time Frame: 0 to 6 months
|
0 to 6 months
|
Clinical URTI and/or LRTI (i.e., no microbiological confirmation)
Time Frame: 0 to 6 months
|
0 to 6 months
|
Clinical URTI (i.e., no microbiological confirmation)
Time Frame: 0 to 6 months
|
0 to 6 months
|
Clinical LRTI (i.e., no microbiological confirmation)
Time Frame: 0 to 6 months
|
0 to 6 months
|
Quantitative S. pneumoniae nasal carriage density
Time Frame: 0 to 6 months
|
0 to 6 months
|
Pneumonia (non-severe) and severe pneumonia or very severe disease
Time Frame: 2 to 6 months
|
2 to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Shaun K Morris, MD, MPH, The Hospital for Sick Children
- Principal Investigator: Daniel Roth, MD, PhD, The Hospital for Sick Children
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Taghivand M, Pell LG, Rahman MZ, Mahmud AA, Ohuma EO, Pullangyeum EM, Ahmed T, Hamer DH, Zlotkin SH, Gubbay JB, Morris SK, Roth DE. Effect of maternal vitamin D supplementation on nasal pneumococcal acquisition, carriage dynamics and carriage density in infants in Dhaka, Bangladesh. BMC Infect Dis. 2022 Jan 13;22(1):52. doi: 10.1186/s12879-022-07032-y.
- Morris SK, Pell LG, Rahman MZ, Dimitris MC, Mahmud A, Islam MM, Ahmed T, Pullenayegum E, Kashem T, Shanta SS, Gubbay J, Papp E, Science M, Zlotkin S, Roth DE. Maternal vitamin D supplementation during pregnancy and lactation to prevent acute respiratory infections in infancy in Dhaka, Bangladesh (MDARI trial): protocol for a prospective cohort study nested within a randomized controlled trial. BMC Pregnancy Childbirth. 2016 Oct 13;16(1):309. doi: 10.1186/s12884-016-1103-9.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2014
Primary Completion (Actual)
August 21, 2016
Study Completion (Actual)
August 21, 2016
Study Registration Dates
First Submitted
March 9, 2015
First Submitted That Met QC Criteria
March 9, 2015
First Posted (Estimate)
March 17, 2015
Study Record Updates
Last Update Posted (Actual)
April 20, 2017
Last Update Submitted That Met QC Criteria
April 18, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000039072-ARI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Upper Respiratory Tract Infections
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)WithdrawnUpper Respiratory Infections
-
University of UtahCompletedUpper Respiratory Infections
-
NovartisNovartis Consumer HealthCompleted
-
Stephen J. Teach, MD, MPHNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingAsthma in Children | Atopy | Viral Upper Respiratory InfectionUnited States
-
BioHealth Technologies Inc.CompletedUpper Respiratory InfectionsUnited States
-
Thomas ErbCompletedUpper Respiratory InfectionsSwitzerland
-
Société des Produits Nestlé (SPN)Completed
-
The Archer-Daniels-Midland CompanyAtlantia Food Clinical TrialsRecruitingUpper Respiratory Tract Infections | Upper Resp Tract InfectionIreland
-
Valenta Pharm JSCCompletedInfluenza | Viral Respiratory Infection | Acute Viral Upper Respiratory InfectionsRussian Federation
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States